Back to List View Graph View

KRAS G12D

KRAS G12D is a point mutation in the KRAS gene that substitutes aspartate for Glycine at codon 12.

Where the papers sit

9 papers from the last 6 months study KRAS G12D directly · updated from PubMed 13 Nov 2026

Study type 0 clinical trials · 4 human data · 4 preclinical · 1 unclassified

Themes one subject · 1 paradigm shift

Those 9 are all about one subject.

  • KRAS G12D Therapeutics

    Selective inhibitors and CRBN-based degraders are driving efforts to treat KRAS G12D cancers, especially metastatic pancreatic cancer. Clinical testing is moving toward allele-specific therapy, while immunotherapy and combinations aim to extend response. Resistance recurs through ANXA1-mediated metabolic reprogramming and MEK/ERK-linked unfolded protein response, with glutamine restriction and nimotuzumab offering reversal strategies. Mutation-sensitive ctDNA assays may support treatment selection and monitoring.

    9 papers

PARADIGM SHIFT

Acquired KRAS G12D-inhibitor resistance can be therapeutically reversed rather than treated as an irreversible failure of allele-specific inhibition

The pancreatic ductal adenocarcinoma study of HRS-4642 resistance and glutamine restriction found that a glutamine-restricted diet reversed resistance through disruption of ANXA1-driven glutamine metabolism and produced remission with prolonged survival 42561948Aug, while the pancreatic cancer study of HRS-4642-resistant cell lines, patient-derived xenografts, and clinical samples found that nimotuzumab reversed resistance by blocking MEK/ERK-mediated unfolded-protein-response reactivation 42303056Jun. Together, these distinct metabolic and signaling interventions show that resistance to KRAS G12D inhibition is not necessarily a terminal loss of drug sensitivity; it can be restored by targeting adaptations that arise during treatment.

Papers

The 9 papers from the last 6 months that study KRAS G12D directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

KRAS G12D Therapeutics (9)
  1. Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018629
  2. Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
  3. Hitting KRAS G12D without the gut punch: Can immunotherapy make it last? Cancer cell · 12 Oct 2026 PMID 42863460
  4. Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
  5. One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
  6. The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
  7. Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming. Cell reports. Medicine · 6 Aug 2026 PMID 42561948
  8. Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Cancer letters · 16 Jun 2026 PMID 42303056
  9. The KRASG12D Inhibitor Pipeline Grows. Cancer discovery · 16 Jun 2026 PMID 42299111

By study type

Human data, design not indexed (4)
  1. Hitting KRAS G12D without the gut punch: Can immunotherapy make it last? Cancer cell · 12 Oct 2026 PMID 42863460
  2. One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
  3. The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
  4. The KRASG12D Inhibitor Pipeline Grows. Cancer discovery · 16 Jun 2026 PMID 42299111
Preclinical: animal, cell and lab studies (4)
  1. Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018629
  2. Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
  3. Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming. Cell reports. Medicine · 6 Aug 2026 PMID 42561948
  4. Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Cancer letters · 16 Jun 2026 PMID 42303056
Unclassified: not yet indexed with MeSH (1)
  1. Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896